MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
1.380
-0.160
-10.39%
Opening 13:16 11/10 EST
OPEN
1.510
PREV CLOSE
1.540
HIGH
1.550
LOW
1.380
VOLUME
21.91K
TURNOVER
--
52 WEEK HIGH
12.60
52 WEEK LOW
1.380
MARKET CAP
23.36M
P/E (TTM)
-0.0272
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAZ last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at RNAZ last week (1026-1030)?
Weekly Report · 11/02 09:20
TransCode Therapeutics, Inc. Initiates Strategic Process to Maximize Value of TTX-MC138 and Oncology Portfolio
NASDAQ · 10/29 08:38
TransCode Therapeutics Initiates Strategic Review of Oncology Portfolio
TipRanks · 10/28 21:21
TransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138
Benzinga · 10/28 20:42
Transcode Therapeutics begins formal strategic process to evaluate opportunities
TipRanks · 10/28 20:41
*Transcode Therapeutics: Will Evaluate Strategic Alternatives Including Licensing Arrangements, Development Partnerships and Other Strategic Transactions >RNAZ
Dow Jones · 10/28 20:36
*Transcode Therapeutics: Lead Program TTX-MC138 Is in Phase 2a Clinical Development for ctDNA-positive Colorectal Cancer Following Curative-Intent Treatment >RNAZ
Dow Jones · 10/28 20:36
More
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.